- Home
- AFRI vs BMEA Comparison
AFRI vs BMEA Comparison
Compare AFRI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFRI
- BMEA
- Stock Information
- Founded
- AFRI 1943
- BMEA 2017
- Country
- AFRI Gibraltar
- BMEA United States
- Employees
- AFRI N/A
- BMEA N/A
- Industry
- AFRI Packaged Foods
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- AFRI Consumer Staples
- BMEA Health Care
- Exchange
- AFRI Nasdaq
- BMEA Nasdaq
- Market Cap
- AFRI 210.6M
- BMEA 65.8M
- IPO Year
- AFRI N/A
- BMEA 2021
- Fundamental
- Price
- AFRI $7.74
- BMEA $1.94
- Analyst Decision
- AFRI
- BMEA Strong Buy
- Analyst Count
- AFRI 0
- BMEA 10
- Target Price
- AFRI N/A
- BMEA $22.30
- AVG Volume (30 Days)
- AFRI 17.3K
- BMEA 2.2M
- Earning Date
- AFRI 07-22-2025
- BMEA 07-30-2025
- Dividend Yield
- AFRI N/A
- BMEA N/A
- EPS Growth
- AFRI N/A
- BMEA N/A
- EPS
- AFRI N/A
- BMEA N/A
- Revenue
- AFRI $274,223,000.00
- BMEA N/A
- Revenue This Year
- AFRI N/A
- BMEA N/A
- Revenue Next Year
- AFRI N/A
- BMEA N/A
- P/E Ratio
- AFRI N/A
- BMEA N/A
- Revenue Growth
- AFRI N/A
- BMEA N/A
- 52 Week Low
- AFRI $7.53
- BMEA $1.29
- 52 Week High
- AFRI $12.00
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- AFRI 44.92
- BMEA 49.92
- Support Level
- AFRI $7.67
- BMEA $1.58
- Resistance Level
- AFRI $7.92
- BMEA $2.01
- Average True Range (ATR)
- AFRI 0.17
- BMEA 0.15
- MACD
- AFRI 0.00
- BMEA 0.01
- Stochastic Oscillator
- AFRI 38.56
- BMEA 80.00
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.